The reduction in the price target by HC Wainwright & Co. suggests a downward revision of the firm's expectations for Allogene Therapeutics' stock performance, which could lead to a negative short-term impact on the stock price. However, the maintenance of a Buy rating indicates the analyst's overall positive outlook on the company, which might mitigate some negative sentiment.